Immatics NV
IMTX6.610USD
+0.580+9.62%
收盘 09/18, 16:00（美东）报价延迟15分钟
803.51M总市值
亏损市盈率 TTM
关于 Immatics NV 公司
Immatics NV 是一家位于荷兰的临床阶段生物制药公司。该公司专注于发现和开发 T 细胞受体，旨在实现针对这些靶标的强大而特异性的 T 细胞反应。该公司开发靶向免疫疗法，重点是通过两种不同的治疗方式治疗实体肿瘤：过继细胞疗法 (ACT) 和抗体样 TCR 双特异性 (TCER)。其全资拥有的管线包括八个治疗项目，其中四个处于临床试验阶段，包括用于实体癌的IMA201（MAGEA4/8）、IMA202（MAGEA1）和ACTolog IMA 101（多目标试点试验）以及用于血液病和实体癌的IMA203（PRAME）；还有四个处于临床前开发阶段，包括用于实体癌的IMA204（COL6A3）和IMA401（癌症睾丸抗原），以及用于血液病和实体癌的ACTallo IMA301（癌症睾丸抗原）和IMA402（癌症睾丸抗原）。
公司简介
公司代码IMTX
公司名称Immatics NV
上市日期Jul 02, 2020
CEODr. Harpreet Singh, Ph.D.
员工数量297
证券类型Ordinary Share
年结日Jul 02
公司地址Paul Ehrlich-Strasse 15
城市TUEBINGEN
上市交易所NASDAQ Capital Market Consolidated
国家Germany
邮编72076
电话4970715397700
网址https://immatics.com/
公司代码IMTX
上市日期Jul 02, 2020
CEODr. Harpreet Singh, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Peter Chambre
Mr. Peter Chambre
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
405.15K
+8.54%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
380.70K
+36.02%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
354.52K
+7.59%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
282.48K
+44.00%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+62.94%
Mr. Edward Sturchio
Mr. Edward Sturchio
General Counsel
General Counsel
200.00K
+87.14%
Mr. Paul Rutherford Carter
Mr. Paul Rutherford Carter
Non-Executive Independent Director
Non-Executive Independent Director
87.19K
+57.63%
Mr. Michael G. (Mike) Atieh
Mr. Michael G. (Mike) Atieh
Non-Executive Independent Director
Non-Executive Independent Director
87.19K
+57.63%
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
Temporary Non-Executive Director
Temporary Non-Executive Director
10.00K
--
Mr. Adam Stone
Mr. Adam Stone
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Peter Chambre
Mr. Peter Chambre
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
405.15K
+8.54%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
380.70K
+36.02%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
354.52K
+7.59%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
282.48K
+44.00%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+62.94%
Mr. Edward Sturchio
Mr. Edward Sturchio
General Counsel
General Counsel
200.00K
+87.14%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
15.08%
DH Capital GmbH & Co. KG
14.15%
Suvretta Capital Management, LLC
9.90%
Baker Bros. Advisors LP
8.37%
Perceptive Advisors LLC
7.72%
其他
44.79%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
15.08%
DH Capital GmbH & Co. KG
14.15%
Suvretta Capital Management, LLC
9.90%
Baker Bros. Advisors LP
8.37%
Perceptive Advisors LLC
7.72%
其他
44.79%
股东类型
持股股东
占比
Hedge Fund
26.41%
Investment Advisor/Hedge Fund
18.84%
Investment Advisor
18.46%
Corporation
18.19%
Private Equity
8.34%
Research Firm
5.08%
Individual Investor
4.66%
Venture Capital
1.84%
Endowment Fund
0.57%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
213
122.33M
100.64%
-17.23M
2025Q1
214
124.44M
102.37%
-14.20M
2024Q4
208
124.50M
104.31%
+7.71M
2024Q3
202
107.38M
100.53%
-7.52M
2024Q2
201
107.32M
100.55%
-1.74M
2024Q1
188
101.29M
94.78%
+19.35M
2023Q4
166
76.94M
93.30%
+2.21M
2023Q3
155
70.38M
86.16%
+3.44M
2023Q2
153
67.89M
85.91%
+7.49M
2023Q1
143
61.60M
80.34%
+3.04M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Investment Management, Inc.
14.68M
12.07%
+524.45K
+3.71%
Mar 31, 2025
DH Capital GmbH & Co. KG
17.20M
14.15%
--
--
Jan 31, 2025
Suvretta Capital Management, LLC
9.14M
7.52%
+1.25M
+15.90%
Mar 31, 2025
Baker Bros. Advisors LP
7.28M
5.99%
--
--
Mar 31, 2025
Perceptive Advisors LLC
9.38M
7.72%
--
--
Mar 31, 2025
RTW Investments L.P.
6.91M
5.68%
+368.97K
+5.64%
Mar 31, 2025
Vestal Point Capital, LP
7.19M
5.92%
+917.70K
+14.62%
Mar 31, 2025
Wellington Management Company, LLP
8.58M
7.06%
-1.83M
-17.61%
Mar 31, 2025
AT Impf GmbH
4.91M
4.04%
--
--
Jan 22, 2024
Woodline Partners LP
1.68M
1.39%
-349.94K
-17.20%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
ALPS Medical Breakthroughs ETF
0.49%
SPDR S&P International Small Cap ETF
0.03%
Fidelity Nasdaq Composite Index ETF
0%
Goldman Sachs Innovate Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
iShares Health Innovation Active ETF
0%
SPDR SSGA US Small Cap Low Volatility Index ETF
0%
SPDR S&P Kensho New Economies Composite ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.68%
ALPS Medical Breakthroughs ETF
占比0.49%
SPDR S&P International Small Cap ETF
占比0.03%
Fidelity Nasdaq Composite Index ETF
占比0%
Goldman Sachs Innovate Equity ETF
占比0%
SPDR Portfolio Developed World ex-US ETF
占比0%
iShares Health Innovation Active ETF
占比0%
SPDR SSGA US Small Cap Low Volatility Index ETF
占比0%
SPDR S&P Kensho New Economies Composite ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
